Seattle Genetics has crossed bars with Clay Siegall’s help
Clay Siegall is a successful entrepreneur and investor. Clay is famed for his venture in biotechnology. He is the one who co-founded Seattle Genetics. Presently he serves as the CEO and the president of the drug company that he co-founded. The firm develops drugs with antibodies that target treatment of cancer patient.
Clay Siegall has diverse and excellent experience in biotechnology. In his career course, he worked with National Institute of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, and National Cancer Institute. Clay Siegall has the track of record and excellent knowledge in healthcare. He was also a board member of directors in Alder BioPharmaceutical. Therefore his idea of coming up with Seattle Genetics was a brilliant move as an investor.
Dr. Clay Siegall has helped Seattle Genetics Company to raise over $ 675 million finances and in developing various antibodies drug pipelines that aim at curing the cancer diseases. Seattle Genetics is renowned Oncology and multi pharmaceutical product in the whole world. It focusses on the production of the antibody-drug conjugate(ADC) which targets human antigens in response to release antibodies in the human immune system that fights against diseases. Consequently, the antibodies attack the cancer cell from inside and release toxic substances which kill the cancer cell. The use of ADC is more advisable as it reduces the danger of exposing healthy human cells to radiations through other therapies like chemotherapy or any other traditional method.
The company developed Adcetris cancer drug which treats lymphatic system cancer that might spread to other body organ and cause severe pain and damage to tissues. 33A is the second in the list which cures myeloid leukemia, the third one is 22ME which targets cancer of the bladder or any other kind of urothelial cancer, and lastly, Seattle Genetics Company launched LIVI which targets the breast cancer. If you have a cancer patient or you are suffering from the disease make an effort and consider using Seattle Genetics products.
Clay Siegall received Ph.D. in Genetics from Washington University and holds B.S in Zoology from the University of Maryland. He has written and published more than seventy publications plus fifteen patents.